Sign up Australia
Proactive Investors - Run By Investors For Investors

Imugene pounces on material acquisition

Imugene is an immuno-oncology company focused on gastric cancer.
Imugene pounces on material acquisition
The company's shares are in pre-open

Imugene Ltd (ASX:IMU) has been a strong performer on the ASX, last trading at 3 cents, or more than double its value in January 2018.

The company recently appointed Ms Leslie Chong as managing director. As CEO, Ms Chong achieved various important milestones in both the clinical and corporate fronts.

The next steps for Imugene will be interesting, with the company this morning entering a trading halt pending details of a material acquisition, and subsequent capital raising.

Currently, Imugene's lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer.

The halt will remain in place until the opening of trade on Thursday 7 June 2018, or earlier if an announcement is made to the market.

View full IMU profile View Profile

Imugene Ltd Timeline

Newswire
October 19 2016

Related Articles

Lung X-Ray
Mon
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use